Therapeutic apheresis treatment in rheumatic diseases: Insights from a single-center experience
Therapeutic Apheresis and Dialysis, cilt.29, sa.1, ss.123-130, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 29 Sayı: 1
- Basım Tarihi: 2025
- Doi Numarası: 10.1111/1744-9987.14199
- Dergi Adı: Therapeutic Apheresis and Dialysis
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
- Sayfa Sayıları: ss.123-130
- Anahtar Kelimeler: catastrophic antiphospholipid antibody syndrome, systemic lupus erythematosus, therapeutic plasma exchange, vasculitis
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Introduction: We aimed to evaluate the characteristics of the patients with a rheumatologic disease who underwent TPE. Method: A single-center, retrospective study was conducted between January 2016 and June 2023. Results: Twenty patients with a median age of 51 years received a median of 6 TPE sessions. Concurrently, immunosuppressive therapy was administered to 18 (90%) of them. During the follow-up period, 9 patients (45%) died. Creatinine (p = 0.001), C-reactive protein (p = 0.001), sedimentation rate (p = 0.002), leukocyte (p = 0.003), thrombocyte (p = 0.003), and neutrophil (p = 0.003) counts was decreased after TPE. Similarly, in the ROC analysis of post TPE laboratory parameters, urea, creatinine, CRP, hemoglobin, platelets, and lymphocytes predicted mortality with areas under the curve values ranging from 0.747 to 0.869. In the Cox regression analysis for mortality, creatinine was predictive for mortality (p = 0.030), HR 1.59 (95% CI: 1.05–2.41). Conclusion: In rheumatologic conditions, TPE is beneficial to fill the gap until the effects of immunosuppressants become apparent.